Amrita Y. Krishnan, MD, Talks Future Analyses for Teclistamab in R/R Multiple Myeloma

Amrita Y. Krishnan, MD, spoke about where future research in multiple myeloma is headed and a take-home message for her colleagues about teclistamab in heavily pretreated patients.

Amrita Y. Krishnan, MD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, professor in the Department of Hematology & Hematopoietic Cell Transplantation, and chief of the Division of Multiple Myeloma at City of Hope spoke with CancerNetwork® at the 2022 American Society of Clinical Oncology Annual Meeting about the evolving landscape of treatments for patients with relapsed/refractory multiple myeloma, including teclistamab and other cellular therapy options.

Krishnan investigated the use of teclistamab in comparison with real-world treatment options for patients with triple-class exposed multiple myeloma who have received 3 or more lines of prior therapy. During treatment, the teclistamab cohort saw better progression-free survival (HR, 0.43; 95% CI, 0.32-0.57; P <.0001), time to next treatment (HR, 0.39; 95% CI, 0.28-0.53; P <.0001), and overall survival (HR, 0.73; 95% CI, 0.50-1.07; P = .1084).

Transcript:

There certainly is a big movement toward using real-world cohorts as comparators as we move ahead with newer myeloma therapies. I do see its place and there are certain challenges in terms of patient-level data vs these large databases. Certainly, I see these analyses being done looking at further variables and as the cohorts grow in the real-world database—such as when the CAR T–treated patients are added to these databases in real numbers and more patients treated with new agents [like] belantamab [mafodotin-blmf; Blenrep]—I do see that these analyses will continue in the future.

Acknowledging the limitations of using a real-world database but also recognizing the absence of data to compare against teclistamab—all the teclistamab data that’s been generated so far is phase 1/2—this was an attempt to try and put it into context of how much of an advantage this is for patients with relapsed/refractory myeloma. I would take that as the take-home [message]. Given the caveats and the limitations of this analysis, it does suggest that this is a very promising new agent for patients with myeloma.

Reference

Krishnan AY, Nooka AK, Chari A, et al. Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2022;40(suppl 16):8036. doi: 10.1200/JCO.2022.40.16_suppl.8036